Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD
Shots:
- The P-IIIb trial evaluating nirsevimab (IM) vs SoC in infants aged ≤12yrs. for the prevention of hospitalizations due to RSV-related LRTD who are not eligible to receive palivizumab at ~250 sites across France, Germany & the UK
- The results showed an 83.21% reduction in hospitalizations due to RSV-related LRTD in a real-world clinical trial setting over infants who received no RSV intervention; 75.71% in the incidence of hospitalizations due to sev. RSV-related LRTD (whose oxygen level is 90% & requires oxygen supplementation)
- 58.04% reduction in the incidence of all-cause LRTD hospitalization & the safety profile was consistent with the pivotal trial. The results were presented at the 41st Annual Meeting of ESPID
Ref: Globenewswire | Image: Sanofi
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
